• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Singular Genomics Systems Inc. (Amendment)

    2/14/24 4:15:49 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $OMIC alert in real time by email
    SC 13G/A 1 ds_2024_sc13ga.htm SC 13G/A SC 13G/A

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

    SCHEDULE 13G

    Information Statement Pursuant to Rules 13d-1 and 13d-2

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

    Singular Genomics Systems, Inc.

    _____________________________________________________

    (Name of Issuer)

    Common Stock, par value of $0.0001 per share

    _____________________________________________________

    (Title of Class of Securities)

    82933R100

    _____________________________________________________

    (CUSIP Number)

    December 31, 2023

    _____________________________________________________

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


     


     

     


     

    CUSIP No. 82933R100

    1.

    Names of Reporting Persons
     

    Andrew Spaventa

     

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

    (a)¨ (b)¨

     

    3.

    SEC USE ONLY

    4.

    Citizenship or Place of Organization

    United States

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

     

    5,958,096 (1)

     

    6.

    Shared Voting Power

    0

     

    7.

    Sole Dispositive Power

     

    5,958,096 (1)

     

    8.

    Shared Dispositive Power

    0

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    5,958,096 (1)

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions) ¨

     

    11.

    Percent of Class Represented by Amount in Row 9

    7.9% (2)

     

    12.

    Type of Reporting Person (see instructions)

    IN

     

    (1)
    Consists of (i) 4,075,789 shares of Common Stock held by The Andrew K. Spaventa Living Trust dated April 9, 2014 (the “Spaventa Living Trust”), (ii) 1,286,429 shares of Common Stock issuable pursuant to options held by the Spaventa Living Trust and have vested or will vest within 60 days of December 31, 2023, (iii) 586,112 shares of Common Stock issuable pursuant to options held directly by Mr. Spaventa and have vested or will vest within 60 days of December 31, 2023, and (iv) 9,766 shares of Common Stock held directly by Mr. Spaventa. Mr. Spaventa is a trustee of the Spaventa Living Trust and has voting and investment control with respect to these shares.
    (2)
    Based on 73,384,510 shares of Common Stock outstanding as of October 31, 2023, as reported on the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 14, 2023 plus the number of shares of Common Stock issuable upon exercise of options exercisable within 60 days of December 31, 2023 held by the Spaventa Living Trust and Mr. Spaventa.


     

     


    Item 1(a).

    Name of Issuer: Singular Genomics Systems, Inc.

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    3010 Science Park Road

    San Diego, CA 92121

     

    Item 2(a).

    Name of Person Filing:

    Andrew Spaventa

    Item 2(b).

    Address of Principal Business Office or, if none, Residence: The address and principal business office of the Reporting Persons is:

    3010 Science Park Road

    San Diego, CA 92121

     

    Item 2(c).

    Citizenship:

    United States of America

    Item 2(d).

    Title of Class of Securities: Common Stock, $0.0001 per share.

     

    Item 2(e).

    CUSIP Number: 82933R100

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

    This statement is not filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c).


     

     



     

    Item 4. Ownership

    (a)

    Amount beneficially owned:

    See Row 9 of cover page for each Reporting Person.

    (b)

    Percent of class:

    See Row 11 of cover page for each Reporting Person.

    (c)

    Number of shares as to which the person has:

    See Row 9 of cover page for each Reporting Person.

    (i)

    Sole power to vote or to direct the vote

    See Row 5 of cover page for each Reporting Person.

    (ii)

    Shared power to vote or to direct the vote

    See Row 6 of cover page for each Reporting Person.

    (iii)

    Sole power to dispose or to direct the disposition of

    See Row 7 of cover page for each Reporting Person.

    (iv)

    Shared power to dispose or to direct the disposition of

    See Row 8 of cover page for each Reporting Person.

    Item 5. Ownership of 5 Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

     

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9. Notice of Dissolution of a Group

    Not applicable.

     

    Item 10. Certification

    Not applicable.


     

     



     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

    Andrew Spaventa

     

    By:

    /s/ Andrew Spaventa

    Name:

    Andrew Spaventa

     


    Get the next $OMIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMIC

    DatePrice TargetRatingAnalyst
    8/17/2022$10.00 → $4.50Buy → Neutral
    UBS
    8/10/2022$3.50Buy → Neutral
    Goldman
    8/10/2022$3.00Buy → Underperform
    BofA Securities
    1/7/2022$21.00Neutral → Buy
    BofA Securities
    10/15/2021Outperform
    Cowen
    More analyst ratings

    $OMIC
    Financials

    Live finance-specific insights

    See more
    • Singular Genomics Reports Recent Updates and Third Quarter 2024 Financial Results

      SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2024. "In the third quarter, we made significant progress in the development of the G4X spatial sequencer," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "We are encouraged by the interest in the G4X and validation received through the expansion of our Spatial Technology Access Services project funnel, which reinfo

      11/12/24 4:05:00 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Reports Recent Highlights and Second Quarter 2024 Financial Results

      SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the second quarter ended June 30, 2024. "It was another busy and productive quarter for our team as we progressed development of the G4X Spatial Sequencer while supporting our G4 customers," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "The early interest in our Spatial Technology Access Services is an encouraging sign that the unique capabilities and

      8/13/24 4:05:00 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics to Report Second Quarter 2024 Financial Results on August 13, 2024

      SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 13, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 1-888-506-0062 for domestic callers or 1-973-528-0011 for international callers and using conference ID 66

      7/30/24 5:05:42 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Leadership Updates

    Live Leadership Updates

    See more
    • Singular Genomics Appoints Genomics Veteran Marcia Eisenberg, Ph.D., to Board of Directors

      SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Marcia Eisenberg, Ph.D., to the Company's Board of Directors. Dr. Eisenberg currently serves as Senior Vice President and Enterprise Chief Scientific Officer at Labcorp (NYSE:LH) and brings more than 30 years of experience with molecular genetics, DNA testing, biotechnology, and molecular oncology. "Marcia's deep and diverse genomics expertise will be an asset to Singular as we drive our business strategy forward, and we are delighted to w

      8/8/23 4:05:00 PM ET
      $LH
      $OMIC
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Appoints Sam Ropp, Ph.D., as Chief Commercial Officer

      SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Sam Ropp, Ph.D., as Chief Commercial Officer. In this role, Dr. Ropp will oversee the company's commercial function, including commercialization of the G4 Sequencing Platform. He will report to Drew Spaventa, Chief Executive Officer and Founder of Singular Genomics. The company also announced the appointment of Jeff Bullard as Head of Sales for North America. "As an accomplished life science leader, Sam brings the deep knowledge and experi

      8/2/22 7:30:00 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Appoints Genomics Research Pioneer Elaine R. Mardis, Ph.D., to Board of Directors

      LA JOLLA, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the addition of Elaine R. Mardis, Ph.D., to the Company's Board of Directors. Dr. Mardis is a pioneering researcher internationally recognized in cancer genomics with a focus on the application of genomic technologies to improve the understanding of human disease and the precision of medical diagnosis, prognosis and treatment. "We are thrilled to have Elaine join the Board of Directors. She brings the rare combination of world-class scientific, indust

      1/6/22 4:05:00 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Singular Highlights Key G4X™ Launch Milestones and Showcases Groundbreaking 3D Spatial Multiomic Performance at AGBT

      SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., an innovator in high-throughput spatial multiomics technologies designed to advance precision medicine, today announced key development milestones for its G4X™ Spatial Sequencer at the Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida. G4X Early Access Program Ongoing and Broader Availability on Track The G4X Early Access Program is currently underway at Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, providing valuable feedback highlighting the platform's real-world potential. "As the first early access site, we've had the chance to

      2/24/25 8:00:00 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Announces Closing of Acquisition by Deerfield Management

      SAN DIEGO, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today the closing of its acquisition by an affiliate of Deerfield Management Company, L.P.    On December 23, 2024, Singular Genomics announced that Deerfield had signed a definitive agreement to acquire all of the outstanding shares of Singular Genomics common stock not currently owned by Deerfield for $20.00 per share in cash. Following the satisfaction of customary conditions, including a vote of the holders of Singular Genomics' common stock to approv

      2/21/25 9:56:26 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Enters into Agreement to be Acquired by Deerfield for $20.00 in Cash per Share

      SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC) ("Singular Genomics" or the "Company"), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it has entered into a definitive merger agreement whereby an affiliate of Deerfield Management Company, L.P. will acquire Singular Genomics in an all-cash transaction for $20.00 per share. The $20.00 per share represents 254% premium to the last closing share price for Singular's common stock prior to the September 12, 2024 public disclosure of Deerfield's initial acquisition proposal. The Singular Genomic

      12/23/24 8:30:00 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tang Kevin bought $1,806,220 worth of shares (122,416 units at $14.75) (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      9/18/24 4:31:08 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Spaventa Andrew bought $49,612 worth of shares (118,468 units at $0.42) (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      11/20/23 4:31:38 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Glezer Eli N. bought $85,640 worth of shares (200,000 units at $0.43), increasing direct ownership by 5% to 4,570,000 units (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      11/20/23 4:30:55 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    SEC Filings

    See more
    • Singular Genomics Systems Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Changes in Control of Registrant

      8-K - Singular Genomics Systems, Inc. (0001850906) (Filer)

      2/27/25 1:42:39 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13D/A filed by Singular Genomics Systems Inc.

      SCHEDULE 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

      2/25/25 9:18:06 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form EFFECT filed by Singular Genomics Systems Inc.

      EFFECT - Singular Genomics Systems, Inc. (0001850906) (Filer)

      2/24/25 12:15:05 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Singular Genomics Systems Inc.

      SC 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

      11/22/24 7:55:51 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13D filed by Singular Genomics Systems Inc.

      SC 13D - Singular Genomics Systems, Inc. (0001850906) (Subject)

      11/5/24 7:29:21 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Singular Genomics Systems Inc.

      SC 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

      11/1/24 7:54:29 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Singular Genomics Systems downgraded by UBS with a new price target

      UBS downgraded Singular Genomics Systems from Buy to Neutral and set a new price target of $4.50 from $10.00 previously

      8/17/22 9:15:00 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Systems downgraded by Goldman with a new price target

      Goldman downgraded Singular Genomics Systems from Buy to Neutral and set a new price target of $3.50

      8/10/22 6:31:06 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Systems downgraded by BofA Securities with a new price target

      BofA Securities downgraded Singular Genomics Systems from Buy to Underperform and set a new price target of $3.00

      8/10/22 6:30:40 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tang Kevin returned 372,000 shares to the company (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      2/27/25 8:54:47 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Executive Officer Spaventa Andrew returned 143,310 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      2/25/25 8:12:58 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Financial Officer Meeter Dalen returned 9,502 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      2/25/25 8:11:40 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials